No products in the cart.
The combination of HMB45, MART-1 and Tyrosinase make this antibody combination a first-order pan melanoma screener. HMB45 has been shown to label the majority of melanomas. MART-1/Melan A is specific to melanocytic lesions. Studies have shown that MART-1 is more sensitive than HMB45 when labeling metastatic melanomas. Tyrosinase has also been shown to be a more sensitive marker when compared to HMB45 and MART-1 and to label a higher percentage of desmoplastic melanomas than HMB45. HMB45 + MART-1 + Tyrosinase Antibody may prove to be a valuable marker for melanoma metastasis in sentinel lymph nodes.
HMB45, M2-7C10 + M2 – 9E3, T311
IgG1/Kappa, IgG2b + IgG2b, IgG2a
HMB45, MART-1, Tyrosinase
1. Orchard G. Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail. Br J Biomed Sci. 2002;59(4):196-20.
2. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, Kissin MW, Powell BW; EORTC Melanoma Group.The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003 Jul;200(3):314-9.
3. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
4. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.